Outcomes in patients receiving continuous monitoring of vital signs on general wards: A systematic review and meta-analysis of randomised controlled trials

Tim Bowles[1,*], Kevin M. Trentino[1,2,*] (iD), Adam Lloyd[1], Laura Trentino[1],
Glynis Jones[3], Kevin Murray[4], Aleesha Thompson[1] (iD), Sarah Halpin[3]
and Grant Waterer[2,5]

Abstract

Objective: The timely identification of deterioration on general wards is crucial to patient care with each hour of delay independently associated with increased risk of death. The introduction of continuous monitoring of patient vital signs on general wards, currently not standard care, may improve patient outcomes. Our aim was to investigate whether patients on general wards receiving continuous vital signs monitoring have better outcomes than patients receiving usual care.

Methods: Meta-analysis of randomised controlled trials comparing non-critical care patients receiving continuous monitoring of vital signs to usual care. We searched Medline, Embase, and Web of Science, and assessed risk of bias with version 2 of the Cochrane risk-of-bias tool for randomised trials. In addition to measures related to the early detection of deterioration, we planned to present all patient outcomes reported by the clinical trials included.

Results: We included seven trials involving 1284 participants. There were no statistically significant differences in the four outcomes pooled. Comparing continuously monitored to normal care, the pooled odds for hospital mortality, major event/complication, and HDU/ICU admission was 0.95 (95% CI 0.59–1.53, $p = 0.84$; 660 participants, 3 studies), 0.71 (95% CI 0.38–1.31, $p = 0.27$; 948 participants, 4 studies) and 0.82 (95% CI 0.25–2.67, $p = 0.74$; 655 participants, 4 studies), respectively. The mean difference for length of stay was 2.12 days lower (95% CI −5.56 to 1.32, $p = 0.23$; 1034 participants, 6 studies).

Conclusion: We found no significant improvements in outcomes for patients continuously monitored compared to usual care. Further research is needed to understand what modalities of continuous monitoring may influence outcomes and investigate the implications of a telepresence service and multi-parameter scoring system.

Registration: PROSPERO CRD42023458656.

Keywords

Digital health, remote patient monitoring, wearables, clinical trials, telehealth, systematic reviews

Submission date: 14 May 2024; Acceptance date: 17 September 2024

[1]Community and Virtual Care Innovation, East Metropolitan Health Service, Perth, Western Australia, Australia
[2]Medical School, The University of Western Australia, Perth, Western Australia, Australia
[3]South Metropolitan Health Service, Fiona Stanley Hospital, Library and Information Service for East and South Metropolitan Health Services, Murdoch, Western Australia, Australia
[4]School of Population and Global Health, The University of Western Australia, Perth, Western Australia, Australia

[5]East Metropolitan Health Service, Perth, Western Australia, Australia
*These authors are joint first authors as they contributed equally to this article.

Corresponding author:
Kevin Trentino, East Metropolitan Health Service, 10 Murray St, Perth, Western Australia 6000, Australia.
Email: kevin.trentino@health.wa.gov.au

Introduction

Rationale

The measurement of patient vital signs was gradually introduced into medical practice in the mid to late 19th century. Today it is common to measure heart rate, respiratory rate, blood pressure, oxygen saturation and temperature in clinical settings. Clinicians measure vital signs to provide patients the best possible care, with vital signs used to detect abnormalities, monitor response to interventions and flag early signs of potential deterioration. Highlighting the considerable potential for patient care, research demonstrates patient deterioration is frequently preceded by abnormal vital sign measures.[1]

As technology advanced electronic devices to continuously monitor patient vital signs started to appear by the mid-20th century.[2] Today it is standard for critical care patients to have their vital signs continuously monitored, while for patients on general wards, standard care remains the manual periodic measurement every 4 to 6 hours. This can be a problem as patients may experience harmful physiological changes and deteriorate between manual readings.[3,4] The timely identification of and response to potential deterioration is critical with one study estimating each hour of delay in admitting a deteriorating patient to intensive care unit (ICU) is independently associated with a 1.5% increased risk of ICU death.[5] It is known that continuous monitoring detects physiological abnormalities that are missed by periodic observations, however, it is not known whether detecting these abnormalities alters outcomes.

Introducing continuous monitoring of patient vital signs on general wards is a potential solution. Patients see the importance of having their vital signs continuously monitored, particularly after-hours, however there are several barriers to implementation.[6] For example, while staff generally appreciate continuous monitoring's potential to enhance patient safety, common issues include perceived increased workload and concerns with ease of technology use.[7] Other barriers include increased false alarms leading to alarm fatigue, patient discomfort with devices, and data capture and storage issues.[3]

Researchers from around the world have conducted useful investigations into the application of continuous vital sign monitoring on general hospital wards.[3,8–10] A previous systematic review and meta-analysis of observational and experimental evidence found patients continuously monitored experienced some improved outcomes when compared to patients receiving normal care with physiological observations being recorded and documented at fixed intervals. However, the authors concluded there was insufficient evidence of effectiveness to recommend routine use of continuous vital sign monitoring in general wards.[11] Their review included studies published up to June 2014 and since then, significant advancements have been made to wireless monitoring technology and techniques to analyse high-frequency patient data. A more recent systematic review and meta-analysis pooled data from observational and experimental studies published up to August 2020 and specifically focused on the impact of wearable devices for the continuous monitoring of vital signs.[12] This study also concluded there was insufficient evidence of improved outcomes in patients whose vital signs were continuously monitored with wearable devices. However, as this review was limited to studies investigating wearable devices only two randomised controlled trials (RCTs) were included in the meta-analysis.

Objectives

There continues to be rapid advancements in healthcare technology and care delivery to detect, escalate and respond to acute deterioration. As such, the effectiveness of continuous monitoring of vital signs on general wards remains unclear. The purpose of this systematic review and meta-analysis was to address this evidence gap by synthesising the results of RCTs using wearable or traditional devices to continuously monitor vital signs in patients on general wards. Our aim was to systematically search the medical literature for the highest and most recent available evidence, comparing outcomes of patients receiving continuously monitored vital signs to patients receiving normal care. Specifically, we sought to answer the question: What are the patient outcomes reported and associated with continuous vital sign monitoring on general wards?

Methods

We registered our protocol on PROSPERO (CRD42023458656) before commencing our review. We based our study methodology on recommendations from the Cochrane Handbook and reported our results in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. Given our systematic review and meta-analysis included data already available in the published literature we did not seek formal ethics approval.

Eligibility criteria

RCTs were eligible for inclusion if they studied inpatients having their vital signs continuously monitored. The comparator group was patients receiving normal care, with intermittent measurement of vital signs. The studies identified needed to be in settings where the continuous monitoring of vital signs is not standard care, that is non-critical care units or recovery wards. To meet inclusion criteria the studies also needed to measure at least one patient

outcome. We excluded studies not published in the English language. Our study group of interest was participants receiving continuous vital signs monitoring. We defined this as patients having at least two vital signs (heart rate, respiratory rate, oxygen saturation or temperature) automatically measured in a continuous manner.

Information sources

Searches were conducted in Medline and Embase (both on the OVID platform) and the Web of Science Core Collection on 5 October 2023. All databases were searched from inception to October 3, 2023. Forward citation chasing of a set of 12 gold standard papers was undertaken using Citation Chaser.[13] Table S1, Supplementary Material lists the publications to which citation searching was applied.

Search strategy

Two experienced health librarians (GJ, SH) developed the search strategies using a combination of free-text (keyword) and thesaurus terms, and this process underwent internal peer review by a third senior librarian. The initial search was developed for Medline and tested against an identified set of 12 gold standard papers (Table S1, Supplementary Material) and subsequently transposed to Embase and Web of Science. The searches were constructed around the concepts of continuous monitoring, vital signs, and general ward inpatients. The searches prioritised sensitivity to maximise retrieval of relevant records with regards the first two concepts; and were adjusted to balance sensitivity and precision with regards to retrieving studies pertaining to inpatients on general hospital wards.

Searches were limited to RCTs. For the Medline search this was done by applying the Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE: sensitivity maximising version (2008 revision).[14] For the Embase search the ISSG Embase RCT filter was applied.[15] The full search strategies for all databases are available in Table S2, Supplementary Material.

Selection and data collection process

Two of the study authors (KT, LT) independently screened the 5108 titles and abstracts returned by the literature search. A third author (TB) independently reviewed a random sample of 700 titles and abstracts. Studies that did not meet inclusion based on the pre-defined eligibility criteria were excluded. Details on the reason for exclusion are available in Table S3, Supplementary Material. Disagreements were first resolved through discussion, followed by resolution with a third independent party. Two authors (KT, LT) performed the data collection process, independently extracting data from eligible RCTs and entering these on standardised data extraction forms. All disagreements arising from the data extraction were resolved by discussion.

Data items

The main outcome initially chosen was any measure related to the early detection of deterioration. In addition, we planned to report all additional patient outcomes which we expected to include mortality, morbidity, ICU transfer, length of hospital stay and length of ICU stay. We used a pre-defined electronic form to extract data on study author details, year of publication, intervention group details, comparison group details, inclusion and exclusion criteria, clinical setting, total number of participants randomised, vital signs measured, subgroups reported and information needed to assess the risk of bias.

Study risk of bias assessment

Two authors (KT, LT) independently assessed the risk of bias in the included studies using Version 2 of the Cochrane risk-of-bias tool for randomised trials (RoB 2). This assessment was done using the RoB 2 electronic tool.[16] In this tool, bias is assessed for each outcome in five distinct domains (randomisation process, deviations from intended interventions, missing outcome data, measurement of the outcome, selection of the reported result), with bias judged as 'low risk of bias', 'some concerns' or 'high risk of bias'. These domain level judgements lead to an overall risk-of-bias judgement for each study outcome.

Effect measures and synthesis methods

We reported dichotomous outcomes as odds ratios (95% confidence intervals [CIs]), and continuous outcomes as mean differences (95% CIs). We planned to synthesise results through meta-analysis where at least three studies reported the same outcome. This decision was consistent with a previously published systematic review and meta-analysis.[11] Where studies did not present standard deviations for continuous outcomes, we planned to obtain them from standard errors or CIs for group means. Where studies presented continuous outcomes as median, minimum, maximum or interquartile range values we estimated the mean and standard deviation of the sample applying techniques described in the literature.[17,18]

Statistical analyses were performed using Review Manager Web (RevMan Web, Version 4.12.0, The Cochrane Collaboration). For our meta-analysis we chose to apply a random-effect meta-analysis model as we expected some heterogeneity between study populations and definitions of outcomes. For binary outcomes we chose the Mantel–Haenszel method to calculate pooled

odds ratios (95% CI), and for continuous outcomes we applied the inverse-variance method and reported the pooled mean difference (95% CI). We examined heterogeneity among pooled studies using the I^2 statistic and the Chi^2 test, and as a rough guide considered Chi^2 test *p*-value above 0.10 and an I^2 statistic under 30% to suggest heterogeneity may not be important. As we identified fewer than 10 studies for inclusion, we did not visually assess the risk of reporting bias using a funnel plot.

Results

Study selection

Figure S1, Supplementary Material summarises the number of studies identified, screened for eligibility and included in our systematic review. After duplicates were removed, our literature search returned 5108 article titles and abstracts, of which 5064 were excluded. Following this, 44 full-text articles[9,19–58] were retrieved and assessed for eligibility and 37 excluded for not meeting our inclusion criteria. More details on exclusion reason are available from Table S3, Supplementary Material. This left 7 RCTs meeting the criteria for inclusion in our review.[36,37,48,54,55]

Study characteristics

Overall, the seven RCTs included in our review randomised a total of 1284 patients in general wards across the UK, Canada, Norway and The Netherlands. Of these 664 were randomised to continuous vital sign monitoring and 620 were allocated to usual care. The characteristics of included studies are presented in Table 1. Four of the studies were conducted in surgical patients,[36,37,48,54] one was conducted in a mixed medical/surgical population[55] and two were in the stroke setting.[59,60] The vital signs continuously measured differed between studies. Two studies[54,55] measured ECG, heart rate, respiratory rate, blood pressure and oxygen saturation, two studies[36,37] measured heart rate, respiratory rate and temperature, two studies[59,60] measured ECG, heart rate, temperature, blood pressure, oxygen saturation and one study[48] measured heart rate and oxygen saturation. The control arm in all studies was normal care, with intermittent measurement of vital signs. The length of continuous monitoring ranged from 24 hours,[54] to the length of patient admission.[36] One study did not report the length of time patients were monitored.[37] Five of the seven trials randomised patients to receive continuous monitoring from wireless devices.[36,37,48,54,59]

A total of 38 patient outcome measures were reported by the included studies. Table S4, Supplementary Material lists all the patient outcomes along with their definitions. The most common patient outcomes were length of stay ($n = 6$),[36,37,54,55,59,60] major events/complications ($n = 4$) as defined by the study authors,[36,37,54,55] HDU/

ICU admissions ($n = 4$)[36,37,48,60] and in-hospital mortality ($n = 3$).[36,55,59] The definition of major complications/events varied from Clavien-Dindo score >2 in two studies[36,37]; unconsciousness, seizure, or stroke in one study[54]; and urgent staff calls, a change to a higher care level, cardiac arrest or death in 96 hours following randomisation in one study.[55]

Risk of bias in studies

We assessed the risk of bias for the 38 individual outcomes included in the seven studies reporting patient outcomes included in this review. The risk of bias assessment for each outcome within each study is available in Figure S2, Supplementary Appendix. In general, we assessed the overall risk of bias to be either 'some concerns' ($n = 33$, 86.8%) or 'low' ($n = 5$, 13.2%). No outcomes were assessed as 'high risk' of bias (Figure 1). The risk of bias assessment for outcomes synthesised by meta-analysis are included in the forest plots and are represented using the traffic light system.

In-hospital mortality

Data on in-hospital mortality were provided in three of the seven studies included in our review.[36,55,59] Overall, these three studies reported 42/357 (11.8%) events in the continuously monitored group and 43/303 events (14.2%) in normal care group. The pooled odds ratio for in-hospital mortality was 0.95 (95% CI 0.59–1.53, $p = 0.84$) times lower in the group receiving continuous monitoring to the group receiving normal care (Figure 2).

Major events/complications

Data on major events/complications were provided in four out of the seven studies included in our review.[36,37,54,55] One study reported significantly fewer major events/complications in the continuously monitored group,[37] the remaining three reported no statistically significant differences between groups.[36,54,55] Overall, these four studies reported 125/497 (25.2%) events in the continuously monitored group and 136/451 events (30.1%) in the normal care group. The pooled odds ratio for a major event/complication was 0.71 (95% CI 0.38–1.31, $p = 0.27$) times lower in the group receiving continuous monitoring to the group receiving normal care (Figure 3).

Length of stay

Six studies presented data on hospital length of stay.[36,37,54,55,59,60] One study reported significantly shorter length of stay in the continuously monitored group.[60] Of the remaining studies, three reported shorter mean length of stay in the continuously monitored group

Table 1. Characteristics of included randomised controlled trials.

| Study	Country	Setting	Inclusion criteria	Total no. randomised	Intervention			Control
					Vital signs measured	Device type	Length of monitoring	
Watkinson 2006	UK	Mixed specialties	High risk adults admitted as medical or surgical emergencies or undergoing major elective surgery (>5% expected complication rate)	402	ECG; Heart rate; Respiratory rate; Blood pressure (30 minutes intervals); Oxygen saturation; Temperature	Standard	72 hours	Manual vital signs monitoring (usual care)
Downey 2020	UK	Gastrointestinal surgery	Adults undergoing elective abdominal surgery	125	Heart rate; Respiratory rate; Temperature	Wireless	Not reported	Manual vital signs monitoring (usual care)
Downey 2018	UK	Elective general surgery	Adults admitted to elective surgical wards	226	Heart rate; Respiratory rate; Temperature	Wireless	Length of admission	Manual vital signs monitoring (usual care)
Paul 2019	Canada	Mixed surgical specialties	Adult surgical patients with an anticipated length of stay > 24 h	250	Heart rate; Oxygen saturation	Wireless	72 hours	Manual vital signs monitoring (usual care)
Skraastad 2020	Norway	Mixed surgery	Adults undergoing acute or elective surgery with expected length of stay > 24 h	195	Heart rate; Respiratory rate; Temperature; Blood pressure; Oxygen saturation; ECG	Wireless	24 hours	Manual vital signs monitoring (usual care)
Sulter 2003	Netherlands	Stroke	Conscious adult acute ischaemic stroke patients in the carotid artery territory with a hemiparesis	54	Heart rate; Temperature; Blood pressure (automatic every 15 min); Oxygen saturation, ECG	Standard	48 hours	Manual vital signs monitoring (usual care)
Langhorne 2010	UK	Stroke	Patients with diagnosis of stroke (either ischaemic or haemorrhagic)	32	Heart rate; Temperature; Blood pressure; Oxygen saturation; ECG	Wireless	72 hours	Manual vital signs monitoring (usual care)

Figure 1. Risk of bias 2 assessments for 38 outcomes reported by 7 randomised controlled trials. Assessed using version 2 of the Cochrane risk-of-bias tool for randomised trials (RoB 2).


Figure 2. In-hospital mortality in patients receiving continuous monitoring for vital signs versus normal care.

when compared to normal care,[36,37,54] while two reported longer mean length of stay,[55,59] however, none of these were statistically significant. The pooled mean difference for length of stay was shorter in the continuously monitored group (mean difference −2.12 days, 95% CI −5.56 to 1.32, $p = 0.23$) (Figure 4).

HDU/ICU admissions

Data on HDU/ICU admissions were available from four studies.[36,37,48,60] These four studies each reported no statistically significant differences in HDU/ICU admissions between groups. The pooled odds ratio for HDU/ICU admission was 0.82 (95% CI 0.25–2.67, $p = 0.74$) times lower in the group receiving continuous vital sign monitoring when compared to the group receiving normal care (Figure 5).

Other patient outcomes

We did not pool the results for any other patient outcomes reported in the included studies. Complications (as defined by the study authors) and 30-day readmissions were available in two studies each and therefore did not meet our minimum criteria for data synthesis.[36,37,59]

For the outcome of any complications (as defined by the study authors) 111/156 had an event in the continuous monitoring group and 63/102 had an event in the intermittent group,[36,59] 30-day readmissions were 22/200 versus 23/151.[36,37] Other outcomes extracted including sepsis, time to antibiotics for sepsis, cardiac arrest team activation, mortality (96 hours and 30-day), supplementary oxygen, time to mobilisation, minor complications,

Figure 3. Major events/complications (as defined by the included studies) in patients receiving continuous monitoring for vital signs versus normal care.


Figure 4. Length of hospital stay in patients receiving continuous monitoring for vital signs versus normal care.

Barthel Index (5-day and 90-day), and respiratory events were only available in one study and therefore could not be pooled. These results are available in Table S4, Supplementary Material.

Subgroup analysis – continuous monitoring using wireless devices

There were no statistically significant differences in patient outcome between the continuous monitoring of vital signs using wireless devices and traditional devices. Occurrences of major events/complications was reported in three studies using wireless continuous monitoring

technology.[36,37,54,59] The pooled odds ratio for a major event/complication was 0.49 (95% CI 0.19–1.26, $p = 0.14$) times lower in the group receiving continuous monitoring, to the group receiving normal care (Figure S3, Supplementary Appendix; test for subgroup differences: $Chi^2 = 1.55$, df = 1, $p = 0.21$). Four studies using wireless continuous monitoring presented data on hospital length of stay.[36,37,54,59] The pooled mean difference for length of stay was 0.53 days (95% CI −1.99 to 0.93, $p = 0.48$) shorter in the continuously monitored group (Figure S4, Supplementary Appendix; Test for subgroup differences: $Chi^2 = 0.47$, df = 1, $p = 0.49$). Three studies with wireless continuous monitoring presented data on HDU/ICU admission. The pooled odds ratio for HDU/ICU admission was

Figure 5. HDU/ICU admission in patients receiving continuous monitoring for vital signs versus normal care.

0.67 (95% CI 0.18–2.53, $p = 0.55$) times lower in the group receiving continuous monitoring to the group receiving normal care (Figure S5, Supplementary Appendix; test for subgroup differences: Chi^2 = 0.74, df = 1, $p = 0.39$).

Discussion

Our systematic review and meta-analysis included seven clinical trials randomising 1284 inpatients to continuous vital sign monitoring or usual care on general wards. The pooled results from our meta-analyses suggest that inpatients receiving continuous monitoring were not less likely to experience in-hospital mortality, have major complications, shorter length of hospital stay or fewer HDU/ICU admissions. However, this conclusion is limited by the low number of studies, relatively low event rate and variability in outcomes reported.

Our results are consistent with previous systematic reviews. A meta-analysis by Areia et al. pooled the results of seven studies and 4127 participants, and reported no statistically significant reductions in mortality (RR 0.48, 95% CI 0.18–1.29), major complications (RR 0.55, 95% CI 0.24–1.30), ICU admission (RR 0.87, 95% CI 0.66–1.15), or mean length of stay (mean difference, −0.09, 95% CI −0.43 to 0.44) with continuous monitoring.[12] Like our results however, these non-statistically significant results favoured continuous monitoring. The main difference between Areia et al. and our study is that they restricted their analysis to wireless monitoring devices and included non-randomised trial designs. A further previous study by Sun et al. pooled nine studies and 12,721 participants and looked at a wide range of devices to continuously monitor vital signs including wired and wireless. They reported a statistically significant reduction in mortality (RR 0.61, 95% CI 0.39–0.95), and non-statistically

significant reductions in ICU admission (RR 0.86, 95% CI 0.67–1.11) and mean length of stay (mean difference −3.32, 95% CI −8.82 to 2.19). Their study however did include studies with a higher risk of bias.[61]

Limitations of the evidence

Significant questions nonetheless remain regarding the outcomes from continuous monitoring. The best patient outcome to measure remains unclear and was variable among the studies identified. The trial providing the largest number of outcome events[55] used a composite outcome, which included urgent escalation calls, as well as cardiac arrests, unplanned ICU transfer or death. The authors conducted a post-hoc analysis separating potentially beneficial events (such as unscheduled escalation to senior medical staff or critical care outreach), from adverse events such as cardiac arrest, with no significant difference identified between the monitoring and standard care groups. When excluding this RCT from our subgroup analysis, the point estimate for major complications favoured the continuously monitored group, though this was not statistically significant. This may be due to the very low number of events remaining after excluding the potentially beneficial ones and therefore benefit from continuously monitoring patients in non-critical care wards cannot be ruled out.

The RCTs included in our review used different combinations of continuous monitoring modalities, and it is possible that different modalities may have different outcomes. There is also uncertainty around the optimal duration of monitoring. One study used a monitoring period of 24 hours, and although two studies[48,55] aimed to apply the monitoring for 72 hours, in one of those trials only 16% of patients were able to be monitored for this whole

duration and 39% were monitored for 24 hours or less.[55] It is possible that this short monitoring period, out of an average hospital length of stay of 3 to 22 days in the various studies, is not adequate to detect a high enough proportion of adverse events to meaningfully alter outcomes.

Another limitation is that the RCTs identified used different inclusion criteria. The largest trial included patients with a calculated risk of death greater than 5%, where the other trials did not specify high risk. The theoretical benefit of continuous monitoring is that early deterioration can be detected and acted upon. It is possible that this benefit is reduced in patients who are already identified as high risk, as they will already be receiving enhanced care. In addition to risk of death, the trials varied in the patient cohort, from elective surgical to stroke to mixed populations.

Monitoring is widely used and generally regarded as safe. The devices used are validated and generally accurate. One study[46] described statistically significant increases in the rate of detection of adverse physiology, including hypotension and hypoxia, without significant changes in the rate of interventions. Alterations in physiology are known to predict patient deterioration. It is therefore unclear why continuous monitoring would not improve outcomes. There are several possible explanations, some of which were addressed in the identified studies.

The monitoring of physiological observations occurs as part of a chain of response, in which as a first step the abnormality must be recognised as such. Unfortunately, the application of continuous monitors to patients who are mobile can create significant volumes of false alarms. This can occur due to interference from movement, or transient physiological changes associated with patient activity such as movement or coughing. It is possible that the resulting alarm fatigue would result in failure of recognition of true abnormalities. A solution to this proposed in one study was the use of a multi-parameter track and trigger system.[55] The National Early Warning Score (NEWS) was used in three of the studies published since 2006, without a significant difference in outcomes observed.

The included RCTs focused on abnormalities detected through continuous monitoring of vital signs, however in addition to the detection of a change in physiology, a robust response to this change must occur. No studies investigated the impact the presence of a medical emergency team (MET) could have had on outcomes. None of the included studies explicitly discussed the effector arm of the monitoring system- who was informed of the monitoring abnormality, and whether there were set responses to abnormalities. The implementation of MET services is now widespread, however, the effect of a MET service on outcomes from continuous monitoring is still unclear. It could act to reduce the effect of the intervention by improving the reliability of response in the control group, or it could enhance the intervention by clear escalation of abnormalities.

A variant of the 'eICU' model was proposed as a solution in one study.[55] This would consist of a remote presence that can act to minimise the number of false alarms by filtering the noise and informing bedside staff of true, actionable alerts. With recent improvements in technology, telehealth systems with a remote presence can act directly on physiological changes to treat developing problems or escalate concerns as appropriate to ward teams. This would therefore act to improve the ability of the continuous monitoring to detect true abnormalities, and to respond appropriately to those abnormalities.

Implications for practice, policy and future research

Our meta-analysis is novel in that it restricted analysis to RCTs, which are considered the gold standard in clinical research. Furthermore, as a recently conducted systematic review, it provides an important update of the current literature incorporating the most recent technological advancements in continuous vital signs measurements. When interpreted with other research, the findings from of our systematic review and meta-analysis are important. Our investigation addresses a gap in current clinical practice as continuous monitoring of vital signs is not routinely performed outside critical care settings. This is a significant issue for inpatient care as high-risk patients on general wards can deteriorate unexpectedly between periodic vital sign recordings, and therefore has implications for safety and quality standards and clinical guidelines.[62]

Current guidelines do not recommend the continuous monitoring of vital signs outside critical care settings and our results do not provide evidence to warrant a change in clinical practice. However, the point estimates for patient outcomes consistently favour continuous monitoring (albeit not statistically significant), and the continuous monitoring technology is improving rapidly. Therefore, it is possible that as more clinical trials are published, and meta-analyses with larger sample sizes are conducted, the results may favour continuously monitoring high-risk patients on general wards over manual intermittent monitoring. In this context our findings may encourage policymakers to consider reviewing and updating guidelines at frequent intervals as new evidence emerges to ensure they are up to date and reflect recent technological developments.

Our meta- analysis has not demonstrated overall benefit to clinical outcomes from continuous monitoring. However, the CIs include benefit, and there remains significant heterogeneity in patient populations who may benefit. Significant research questions remain, including:

- What modalities of continuous monitoring have most beneficial effect on outcomes?
- Which patient groups are most likely to benefit from continuous monitoring?

- Does the addition of a telepresence service to maintain and filter the continuous monitoring, and action the results, alter the benefits of continuous monitoring?
- Does the development of multi-parameter scoring systems utilising the continuous monitoring, where false alarms are filtered, improve the outcomes associated with continuous monitoring?
- Where multi-parameter models are used, which is most effective, and which elements are most important?
- Current multi-parameter models look at multiple parameters at a single time point. How does the use of time averaged or time-trend data alter the performance of multi-parameter models?
- What are the health economic implications of implementation of continuous monitoring systems, and are they cost effective in improving patient-orientated or health service orientated outcomes?

A fundamental problem with studying any monitoring modality is that the monitoring in isolation forms only part of a clinical process, which extends from alteration in patient state, detection of that alteration, activation of a response, to confirmation of resolution of alteration or escalation of care if needed. Changes to one element- the monitoring, is unlikely to be effective unless matched by an appropriate response. We would recommend future research includes a response system, as well as detection. In this context, future trials of the intervention are unlikely to be feasible at individual patient level and will likely require ward or hospital level randomisation.

Conclusion

We found no significant improvements in outcomes for patients continuously monitored compared to normal care. However, this conclusion is limited by the low number of studies, relatively low event rate, and variability in outcomes reported. As vital sign monitoring technologies continue to advance, and more clinical trials and meta-analyses are conducted there may be some patient groups where continuous monitoring is proved beneficial. More research is needed to understand what modalities of continuous monitoring may influence outcomes and investigate the implications of a telepresence service and multi-parameter scoring system.

ORCID iD: Kevin M. Trentino (iD) https://orcid.org/0000-0002-8768-9263
Aleesha Thompson (iD) https://orcid.org/0009-0004-9866-0089

References

1. Downey CL, Tahir W, Randell R, et al. Strengths and limitations of early warning scores: a systematic review and narrative synthesis. *Int J Nurs Stud* 2017; 76: 106–119.
2. Himmelstein A and Scheiner M. The cardiotachoscope. *Anesthesiology* 1952; 13: 62–64.
3. Downey CL, Chapman S, Randell R, et al. The impact of continuous versus intermittent vital signs monitoring in hospitals: a systematic review and narrative synthesis. *Int J Nurs Stud* 2018; 84: 19–27.
4. Trentino KM, Schwarzbauer K, Mitterecker A, et al. Machine learning-based mortality prediction of patients at risk during hospital admission. *J Patient Saf* 2022; 18: 494–498.
5. Cardoso LTQ, Grion CMC, Matsuo T, et al. Impact of delayed admission to intensive care units on mortality of critically ill patients: a cohort study. *Crit Care* 2011; 15: R28.
6. Downey CL, Brown JM, Jayne DG, et al. Patient attitudes towards remote continuous vital signs monitoring on general surgery wards: an interview study. *Int J Med Inform* 2018; 114: 52–56.
7. Downey C, Brown J, Jayne D, et al. Nursing staff perspectives of continuous remote vital signs monitoring on surgical wards: theory elicitation for a realist evaluation. *J Eval Clin Pract* 2022; 28: 394–403.
8. Sigvardt E, Gronbaek KK, Jepsen ML, et al. Workload associated with manual assessment of vital signs as compared with

continuous wireless monitoring. *Acta Anaesthesiol Scand* 2024; 68: 274–279.

9. Weenk M, Bredie SJ, Koeneman M, et al. Continuous monitoring of vital signs in the general ward using wearable devices: randomized controlled trial. *J Med Internet Res* 2020; 22: e15471.

10. Bowles T, Trentino KM, Lloyd A, et al. Health in a virtual environment (HIVE): a novel continuous remote monitoring service for inpatient management. *Healthcare* 2024; 12: 1265.

11. Cardona-Morrell M, Prgomet M, Turner RM, et al. Effectiveness of continuous or intermittent vital signs monitoring in preventing adverse events on general wards: a systematic review and meta-analysis. *Int J Clin Pract* 2016; 70: 806–824.

12. Areia C, Biggs C, Santos M, et al. The impact of wearable continuous vital sign monitoring on deterioration detection and clinical outcomes in hospitalised patients: a systematic review and meta-analysis. *Crit Care* 2021; 25: 351.

13. Haddaway NR, Grainger MJ and Gray CT. citationchaser: an R package and Shiny app for forward and backward citations chasing in academic searching. 2021. https://estech.shinyapps.io/citationchaser/.

14. Lefebvre C, Glanville J, Briscoe S, et al. Technical supplement to chapter 4: searching for and selecting studies. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ and Welch VA (eds) *Cochrane handbook for systematic reviews of interventions version 6.3*. Chichester, UK: John Wiley & Sons, 2022, pp.1–121. www.training.cochrane.org/handbook (2022, accessed September 27 2023).

15. Glanville J. Embase RCT filter for OVID 30 April 2023 Revision., https://sites.google.com/a/york.ac.uk/issg-search-filters-resource/home/rcts/embase-rct-filter (accessed September 27 2023).

16. Sterne JAC, Savovic J, Page MJ, et al. Rob 2: a revised tool for assessing risk of bias in randomised trials. *Br Med J* 2019; 366: l4898.

17. Luo D, Wan X, Liu J, et al. Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. *Stat Methods Med Res* 2018; 27: 1785–1805.

18. Wan X, Wang W, Liu J, et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. *BMC Med Res Methodol* 2014; 14: 135.

19. Abraham WT, Adamson PB, Bourge RC, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. *Lancet* 2011; 377: 658–666.

20. Achury DM, Garcia AG, Marino AM, et al. Efficacy of controlvit as a complementary strategy in reducing hospitalizations in patients with heart failure. Randomized clinical trial. *Eur Respir J* 2022; 60: 2820. Conference Abstract.

21. Aggarwal R, Gunaseelan V, Manual D, et al. Clinical evaluation of a wireless device for monitoring vitals in newborn babies. *Indian J Pediatr* 2023; 90: 1110–1115.

22. Aktas M, An Q, Boehmer J, et al. Continuous respiratory rate is superior to routine outpatient dyspnea assessment for predicting heart failure events. *Heart Lung* 2020; 49: 215. Conference Abstract.

23. Al Rajeh AM, Aldabayan YS, Aldhahir A, et al. Once daily versus overnight and symptom versus physiological monitoring to detect exacerbations of chronic obstructive pulmonary disease: pilot randomized controlled trial. *JMIR mHealth UHealth* 2020; 8: e17597.

24. Ayhan A, Akovalı N and Camkıran Firat A. Can hypotension episodes that were not identified in the non-invasive blood pressure be detected during cesarean section? A randomized controlled trial. *Balk Med J* 2022; 39: 358–365. Article.

25. Bierman MI, Stein KL and Snyder JV. Pulse oximetry in the postoperative care of cardiac surgical patients. A randomized controlled trail. *Chest* 1992; 102: 1367–1370.

26. Bonnici TA. Early detection of inpatient deterioration using wearable monitors. Thesis submitted in fulfilment of the requirements for the degree of Doctor of Philosophy 2019.

27. Bourge RC, Abraham WT, Adamson PB, et al. Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure – the COMPASS-HF study. *J Am Coll Cardiol* 2008; 51: 1073–1079. Article.

28. Boyne J, Vrijhoef HJ, Nieman FH, et al. Telemonitoring in patients with heart failure: results from a multicenter randomized controlled trial (the tehaf study). *J Am Coll Cardiol* 2011; 57: E389. Conference Abstract.

29. Boyne JJJ, Vrijhoef HJM, Crijns H, et al. Tailored telemonitoring in patients with heart failure: results of a multicentre randomized controlled trial. *Eur J Heart Fail* 2012; 14: 791–801. Article.

30. Brahmbhatt DH, Ross HJ, Sullivan MO, et al. Use of a remote telemonitoring platform significantly improves medication optimisation in heart failure patients. *Eur Respir J* 2022; 60: 1094. Conference Abstract.

31. Broens SJL, Prins SA, de Kleer D, et al. Postoperative respiratory state assessment using the Integrated Pulmonary Index (IPI) and resultant nurse interventions in the post-anesthesia care unit: a randomized controlled trial. *J. Clin. Monit. Comput.* 2021; 35: 1093–1102.

32. Brown H, Terrence J, Vasquez P, et al. Continuous monitoring in an inpatient medical-surgical unit: a controlled clinical trial. *Am J Med* 2014; 127: 226–232.

33. Chia X, Chan J, Sinnappan R, et al. Use of non-invasive continuous respiratory rate and oxygen saturation monitoring through a finger probe for postoperative patient-controlled analgesia: a pilot study. *Anaesthesia* 2018; 73: 88–88. Meeting Abstract.

34. Crossley GH, Boyle A, Vitense H, et al. The CONNECT (clinical evaluation of remote notification to reduce time to clinical decision) trial the value of wireless remote monitoring with automatic clinician alerts. *J Am Coll Cardiol* 2011; 57: 1181–1189. Article.

35. Downey C, Randell R, Brown J, et al. Continuous versus intermittent vital signs monitoring in patients admitted to surgical wards: a cluster-randomised, controlled trial. *Colorectal Dis* 2018; 20: 60. Conference Abstract.

36. Downey C, Randell R, Brown J, et al. Continuous versus intermittent vital signs monitoring using a wearable, wireless patch in patients admitted to surgical wards: pilot cluster randomized controlled trial. *J Med Internet Res* 2018; 20: e10802. Article.

37. Downey CL, Croft J, Ainsworth G, et al. Trial of remote continuous versus intermittent NEWS monitoring after major surgery (TRaCINg): a feasibility randomised controlled trial. *Pilot Feasibility Stud* 2020; 6: 183.

38. Fortmann AL, Spierling Bagsic SR, Talavera L, et al. Glucose as the fifth vital sign: a randomized controlled trial of continuous glucose monitoring in a non-ICU hospital setting. *Diabetes Care* 2020; 43: 2873–2877.

39. Gonzalez B, Domingo M, Lupon J, et al. Use of telemedicine (Motiva-Philips) in an heart failure unit: changes in patient's behaviour and impact on quality of life: the CARME study (CAtalan Remote Management Evaluation). *Eur J Heart Fail* 2010; 1: S108. Conference Abstract.

40. Han WH, Sohn DK, Hwangbo Y, et al. Effect of a wireless vital sign monitoring system on the rapid response system in the general ward. *J Med Syst* 2022; 46: 64.

41. Herbst A and Ingemarsson I. Intermittent versus continuous electronic monitoring in labour: a randomised study. *Br J Obstet Gynaecol* 1994; 101: 663–668.

42. Mahant S, Wahi G, Bayliss A, et al. Intermittent vs continuous pulse oximetry in hospitalized infants with stabilized bronchiolitis: a randomized clinical trial. *JAMA Pediatr* 2021; 175: 466–474.

43. McCulloh R, Koster M, Ralston S, et al. Use of intermittent vs continuous pulse oximetry for nonhypoxemic infants and young children hospitalized for bronchiolitis: a randomized clinical trial. *JAMA Pediatr* 2015; 169: 898–904.

44. Moretti ME, Jegathisawaran J, Wahi G, et al. Cost-effectiveness of intermittent vs continuous pulse oximetry monitoring in infants hospitalized with stabilized bronchiolitis. *JAMA Network Open* 2022; 5: e2243609.

45. Muppidi PR, Murki S, Kiran S, et al. Tempwatch for monitoring hypothermia in very-low-birth-weight infants: a randomized controlled trial. *Perinatology* 2020; 20: 108–113.

46. Noll ML. Pulse oximetry in the postoperative care of cardiac surgical patients: a randomized clinical trial. (Bierman MI, Stein KL, Snyder JV. Chest 1992; 102: 1367-70.). *Heart Lung J Crit Care* 1993; 22: 278–281. Review.

47. Paniagua R, Avila M, Ramos A, et al. Remote monitoring of patients with automated peritoneal dialysis may improve clinical outcomes: analysis by competing-risk regression models. *J Am Soc Nephrol* 2021; 32: 327. Conference Abstract.

48. Paul JE, Chong MA, Buckley N, et al. Vital sign monitoring with continuous pulse oximetry and wireless clinical notification after surgery (the VIGILANCE pilot study)-a randomized controlled pilot trial. *Pilot Feasibility Stud* 2019; 5: 36.

49. Pedone C, Chiurco D, Scarlata S, et al. Efficacy of multiparametric telemonitoring on respiratory outcomes in elderly people with COPD: a randomized controlled trial. *BMC Health Serv Res* 2013; 13: 7. Article.

50. Pedone C, Rossi FF, Cecere A, et al. Efficacy of a physician-led multiparametric telemonitoring system in very old adults with heart failure. *J Am Geriatr Soc* 2015; 63: 1175–1180.

51. Petersen JA, Antonsen K and Rasmussen LS. Frequency of early warning score assessment and clinical deterioration in hospitalized patients: a randomized trial. *Resuscitation* 2016; 101: 91–96.

52. Pietrantonio F, Vinci A, Rosiello F, et al. Green line hospital-territory study: a single-blind randomized clinical trial for evaluation of technological challenges of continuous wireless monitoring in internal medicine, preliminary results. *Int J Environ Res Public Health* 2021; 18: 12. Article.

53. Sankar J, Singh M, Kumar K, et al. 'Intermittent' versus 'continuous' ScvO(2) monitoring in children with septic shock: a randomised, non-inferiority trial. *Intensive Care Med* 2020; 46: 82–92.

54. Skraastad EJ, Borchgrevink PC, Nilsen TIL, et al. Postoperative quality and safety using Efficacy Safety Score (ESS) and a wireless patient monitoring system at the ward: a randomised controlled study. *Acta Anaesthesiol Scand* 2020; 64: 301–308.

55. Watkinson PJ, Barber VS, Price JD, et al. A randomised controlled trial of the effect of continuous electronic physiological monitoring on the adverse event rate in high risk medical and surgical patients. *Anaesthesia* 2006; 61: 1031–1039.

56. Weenk M, Koeneman M, van de Belt TH, et al. Wireless and continuous monitoring of vital signs in patients at the general ward. *Resuscitation* 2019; 136: 47–53.

57. Weenk M, van Goor H, Frietman B, et al. Continuous monitoring of vital signs using wearable devices on the general ward: pilot study. *JMIR mHealth UHealth* 2017; 5: e91. Article.

58. Wong DCW, Knight J, Birks J, et al. Impact of electronic versus paper vital sign observations on length of stay in trauma patients: stepped-wedge, cluster randomized controlled trial. *JMIR Med Inform* 2018; 6: e10221.

59. Langhorne P, Stott D, Knight A, et al. Very early rehabilitation or intensive telemetry after stroke: a pilot randomised trial. *Cerebrovasc Dis* 2010; 29: 352–360.

60. Sulter G, Elting JW, Langedijk M, et al. Admitting acute ischemic stroke patients to a stroke care monitoring unit versus a conventional stroke unit: a randomized pilot study. *Stroke* 2003; 34: 101–104.

61. Sun L, Joshi M, Khan SN, et al. Clinical impact of multiparameter continuous non-invasive monitoring in hospital wards: a systematic review and meta-analysis. *J R Soc Med* 2020; 113: 217–224.

62. Australian Commission on Safety and Quality in Health Care. *Detecting and recognising acute deterioration, and escalating care*. Sydney: ACSQHC, 2024.